Our top pick for
STERIS plc is a medical instruments & supplies business based in the US. STERIS shares (STE) are listed on the NYSE and all prices are listed in US Dollars. STERIS employs 13,000 staff and has a trailing 12-month revenue of around USD$3 billion.
|Latest market close||USD$189.54|
|52-week range||USD$104.9575 - USD$196.42|
|50-day moving average||USD$187.0369|
|200-day moving average||USD$166.3399|
|Wall St. target price||USD$200|
|Dividend yield||USD$1.6 (0.85%)|
|Earnings per share (TTM)||USD$4.93|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-06)||-2.92%|
|1 month (2020-12-15)||0.69%|
|3 months (2020-10-13)||0.99%|
|6 months (2020-07-13)||26.23%|
|1 year (2020-01-13)||25.08%|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||182.90%|
Valuing STERIS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of STERIS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
STERIS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, STERIS shares trade at around 39x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
STERIS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.0038. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into STERIS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
STERIS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$781.4 million.
The EBITDA is a measure of a STERIS's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$3 billion|
|Operating margin TTM||19.11%|
|Gross profit TTM||USD$1.3 billion|
|Return on assets TTM||6.76%|
|Return on equity TTM||12.23%|
|Market capitalisation||USD$16.2 billion|
TTM: trailing 12 months
There are currently 938,807 STERIS shares held short by investors – that's known as STERIS's "short interest". This figure is 19% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting STERIS shares can be evaluated.
STERIS's "short interest ratio" (SIR) is the quantity of STERIS shares currently shorted divided by the average quantity of STERIS shares traded daily (recently around 327110.45296167). STERIS's SIR currently stands at 2.87. In other words for every 100,000 STERIS shares traded daily on the market, roughly 2870 shares are currently held short.
However STERIS's short interest can also be evaluated against the total number of STERIS shares, or, against the total number of tradable STERIS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case STERIS's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 STERIS shares in existence, roughly 10 shares are currently held short) or 0.0124% of the tradable shares (for every 100,000 tradable STERIS shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against STERIS.
Find out more about how you can short STERIS stock.
Dividend payout ratio: 26.19% of net profits
Recently STERIS has paid out, on average, around 26.19% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.85% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), STERIS shareholders could enjoy a 0.85% return on their shares, in the form of dividend payments. In STERIS's case, that would currently equate to about $1.6 per share.
While STERIS's payout ratio might seem fairly standard, it's worth remembering that STERIS may be investing much of the rest of its net profits in future growth.
STERIS's most recent dividend payout was on 18 December 2020. The latest dividend was paid out to all shareholders who bought their shares by 23 November 2020 (the "ex-dividend date").
STERIS's shares were split on a 2:1 basis on 25 August 1998. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your STERIS shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for STERIS shares which in turn could have impacted STERIS's share price.
Over the last 12 months, STERIS's shares have ranged in value from as little as $104.9575 up to $196.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while STERIS's is 0.5896. This would suggest that STERIS's shares are less volatile than average (for this exchange).
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.